Ameliorative Effects of Infantile Feire Kechuan Oral Solution on Mycoplasma Pneumoniae Pneumonia in Infant Mouse and Rat Models

Guo, Shan-Shan; Bao, Lei; Qu, Tiange; Mao, Xin; Gao, Yingjie; Xu, Yingli; Cui, Xiaolan

doi:10.1155/2018/8139040

Cited by 7 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The blood samples were centrifuged at 3000 rpm for 10 min, and the serum was stored at −20 °C for analysis (Guo et al. 2018 ). The right lung was ligated, and normal saline was injected from the trachea to the left lung twice, 1.5 mL each time.…”

Section: Methodsmentioning

confidence: 99%

“…Blood (5 mL) was collected from the abdominal aorta and placed in an anticoagulant vacuum blood container without additives. The blood samples were centrifuged at 3000 rpm for 10 min, and the serum was stored at À20 C for analysis (Guo et al 2018). The right lung was ligated, and normal saline was injected from the trachea to the left lung twice, 1.5 mL each time.…”

Section: Experimental Animalmentioning

confidence: 99%

See 1 more Smart Citation

Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology

Han

Jing

et al. 2021

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: Re-yan-ning mixture (RYNM) is a new national drug approved by China's State Food and Drug Administration for the treatment of colds, simple pneumonia and acute bronchitis. Objective: To determine the mechanism of action of RYNM in the treatment of bacterial pneumonia. Materials and methods: Using the network pharmacology approach, the multiple components, component candidate targets and multiple therapeutic targets of RYNM were screened and functionally enriched. Also, we established a rat Streptococcus pneumonia model to verify the results of network pharmacology enrichment analysis. Forty male SPF Sprague Dawley rats were divided into four groups of 10 rats: control (normal saline), model (normal saline), levofloxacin-intervened and RYNM-intervened groups. IL-10, NOS2, COX-1, IL-6, TNF-a and NF-jB in serum and BALF were detected by ELISA. Western blot detected IL-17, IL-6, TNF-a, COX-2 and Bcl-2. Results: The network pharmacology approach successfully identified 48 bioactive components in RYNM, and 65 potential targets and 138 signal pathways involved in the treatment of Streptococcus pneumonia with RYNM. The in vivo experiments indicated that model group has visible inflammation and lesions while RYNM and levofloxacin groups have not. The RYNM exhibited its therapeutic effects on Streptococcus pneumonia mainly via the regulation of cell proliferation and survival through the IL-6/IL-10/IL-17, Bax/Bcl-2, COX-1/COX-2, NF-jB and TNF-a signalling pathways. Discussion and conclusions: The present study demonstrated the protective effects of RYNM on Streptococcus pneumonia, providing a potential mechanism for the treatment of bacterial pneumonia with RYNM.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Experimental Animalmentioning

confidence: 99%

Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology

Han

Jing

et al. 2021

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…TCMOLs have been used not only for MPP but also for other acute upper respiratory infections (Gao et al, 2015). In addition, TCMOLs may also have anti-inflammatory, immunoregulation, and IgM response-suppressive effects (Guo et al, 2018;Shi et al, 2020). Although some studies have reported on the effects of TCMOLs, the TCMOL with highest efficacy against MPP in children has not been identified.…”

Section: Introductionmentioning

confidence: 99%

Traditional Chinese Medicine Oral Liquids Combined With Azithromycin for Mycoplasma pneumoniae Pneumonia in Children: A Bayesian Network Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background:Mycoplasma pneumoniae pneumonia (MPP) causes flu-like symptoms in children, increasing the burden on the health and education systems. In China, traditional Chinese medicine oral liquids (TCMOLs) combined with azithromycin (TCMOLs + Azithromycin) is commonly used to treat MPP in children. However, TCMOLs with the optimal clinical applicability remain unknown. Here, we evaluated the clinical effectiveness and safety of TCMOLs + Azithromycin in children with MPP.Methods: We searched PubMed, Embase, Cochrane Library, Ovid, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, and VIP information resource integration service platform databases for eligible randomized controlled trials (RCTs) published from database inception to October 2020. Two reviewers independently performed data extraction and risk of bias assessment. After Bayesian random effect modeling and surface under the cumulative ranking curve (SUCRA) scoring, we ranked each intervention. We assessed heterogeneity using multivariate meta-regression for potential modifiers and used the Grading of Recommendations, Assessment, Development, and Evaluation to rate pooled evidence’s certainty.Results: In the 63 included RCTs with 6,410 children, five different TCMOLs were combined with azithromycin. TCMOLs + Azithromycin had significantly better primary outcomes than did azithromycin alone. Of all TCMOLs, Xiaoer Xiaoji Zhike (XEXJZK)+Azithromycin showed the best effectiveness with respect to the response rate (odds ratio [OR] = 6.5, 95% credible interval [CrI] = 4.3–10; low certainty) and pulmonary rales disappearance time (mean difference [MD] = −2.1, 95% CrI: −2.9 to −1.2; low certainty) with SUCRA 85 and 80%, respectively. Pudilan Xiaoyan + Azithromycin showed the highest effectiveness with respect to cough disappearance time (MD = −2.6, 95% CrI: −3.4 to −1.7; very low certainty) and fever disappearance time (MD = −1.8, 95% CrI: −2.3 to −1.3; very low certainty) with SUCRA 87 and 87%, respectively. The difference in the adverse effects between TCMOLs + Azithromycin and azithromycin alone was nonsignificant.Conclusion: Of the different TCMOLs, XEXJZK may be the best option to combine with azithromycin to treat children with MPP. However, our results should be interpreted with caution due to the low certainty of evidence. In general, TCMOLs’ safety remains unclear because of a lack of evidence. More high-quality RCTs are needed to further evaluate efficacy and safety of these TCMOLs.

show abstract

“…Infantile mycoplasmal pneumonia is one of the main causes of respiratory infection in children (2). If not treated in time, it may cause bronchiectasis, atelectasis and pulmonary interstitial brosis, and even death in severe cases (3).…”

Section: Introductionmentioning

confidence: 99%

“…At present, the etiology of infantile pneumonia is not completely clear, which might be associated with the humoral and cellular immunity of the children (3). Therefore, anti-infection and symptomatic treatment are the main therapeutic approaches.…”

Section: Introductionmentioning

confidence: 99%

Dapk1 promoted inflammation of infantile pneumonia by p38MAPK/NF-κB signaling pathway

Zhang

2021

Mol. Cell. Toxicol.

View full text Add to dashboard Cite

Ameliorative Effects of Infantile Feire Kechuan Oral Solution on Mycoplasma Pneumoniae Pneumonia in Infant Mouse and Rat Models

Cited by 7 publications

References 42 publications

Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology

Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology

Traditional Chinese Medicine Oral Liquids Combined With Azithromycin for Mycoplasma pneumoniae Pneumonia in Children: A Bayesian Network Meta-Analysis

Dapk1 promoted inflammation of infantile pneumonia by p38MAPK/NF-κB signaling pathway

Contact Info

Product

Resources

About